Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
Avidity unveiled "impressive" results from a study of its treatment for a rare form of muscular dystrophy. The top biotech stock soared.
These two biotechnology stocks could be gearing up for a run.